Business News • PR NewsWire • Approximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data

Approximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data

Approximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data

EAST HANOVER, N.J., Nov. 7, 2015 /PRNewswire/ -- Novartis announced two-year data for Cosentyx® (secukinumab) from an observational sub-analysis of a pivotal Phase III trial showing no progression of radiographic joint damage in approximately 84% of patients treated over a...

View More : http://www.prnewswire.com/news-releases/approximately-80-of-psoriatic-arthritis-patients-treated-with-cosentyx-saw-no-pr...

Releted News by prnewswire

goExW '50% Off' Thanksgiving Campaign Boosts Wholesale Imports Proposition

U.S. Census Bureau Daily Feature for November 8: First Popularly Elected Black Senator

Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles in One-Year Phase 3 Clinical Studies

Approximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data

Boehringer Ingelheim Highlights Latest Community and Research Initiatives in Advancing Anticoagulation Care at American Heart Association (AHA) Scientific Sessions 2015

High Quality Medical Cannabis Legally Available in Illinois for First Time Ever